In agreement with these previous studies, we showed that CARM1 is overexpressed in human ovarian cancers (30/84, 35.7%), with significant correlation of high NAC1 expression levels, and elevated levels of NAC1 and CARM1 correlate with poor prognosis after adjuvant chemotherapy (Figure 3C). This evidence concerns the gene CARM1 and ovarian cancer.